Significance of lymph node involvement in local recurrence of colorectal cancer.


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 24 05 2019
accepted: 24 06 2019
pubmed: 25 7 2019
medline: 7 9 2019
entrez: 24 7 2019
Statut: ppublish

Résumé

There are few data on lymphatic spread concomitant to local recurrence (LR) of colorectal cancer (CRC). The objectives of this study were to determine variables associated with lymphatic spread, to analyze the distribution of LN+, and understand the underlying mechanisms. A total of 76 patients underwent resection of LR of CRC between January 2007 and December 2018 at Institut cancérologique de l'Ouest and were retrospectively reviewed. Twenty-five (32.9%) patients had lymph node (LN) involvement with LR. Lymphatics from the mesocolon-rectum and aorto-iliac compartments were involved in 21%, 20.3% and 18.1%, 20.3% for pelvic and retroperitoneal LRs, respectively. In multivariate analysis, the only predictive factor for LN invasion (LN+) was a primary positive LN status (odds ratio, 5.3; P = .007). Despite a trend toward a worse median overall survival in the LN+ group, the difference was not significant in comparison with the LN- group (46 vs. 57 months; P = 0.31) or with the LN- plus LN not assessed groups (46 months vs not reached; P = .07). LN invasion with LR from CRC is a frequent occurrence without significant impact on survival. The only predictive factor is a primary positive nodal status.

Sections du résumé

BACKGROUND BACKGROUND
There are few data on lymphatic spread concomitant to local recurrence (LR) of colorectal cancer (CRC). The objectives of this study were to determine variables associated with lymphatic spread, to analyze the distribution of LN+, and understand the underlying mechanisms.
METHODS METHODS
A total of 76 patients underwent resection of LR of CRC between January 2007 and December 2018 at Institut cancérologique de l'Ouest and were retrospectively reviewed.
RESULTS RESULTS
Twenty-five (32.9%) patients had lymph node (LN) involvement with LR. Lymphatics from the mesocolon-rectum and aorto-iliac compartments were involved in 21%, 20.3% and 18.1%, 20.3% for pelvic and retroperitoneal LRs, respectively. In multivariate analysis, the only predictive factor for LN invasion (LN+) was a primary positive LN status (odds ratio, 5.3; P = .007). Despite a trend toward a worse median overall survival in the LN+ group, the difference was not significant in comparison with the LN- group (46 vs. 57 months; P = 0.31) or with the LN- plus LN not assessed groups (46 months vs not reached; P = .07).
CONCLUSIONS CONCLUSIONS
LN invasion with LR from CRC is a frequent occurrence without significant impact on survival. The only predictive factor is a primary positive nodal status.

Identifiants

pubmed: 31332806
doi: 10.1002/jso.25631
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

722-728

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Frédéric Dumont (F)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Miguel A Muñoz (MA)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Valéria De Franco (V)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France.

Romuald Wernert (R)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France.

Valérie Verriele (V)

Department of Pathology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France.

Marie-Françoise Heyman (MF)

Department of Pathology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France.

Olivier Kerdraon (O)

Department of Pathology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France.

Olivier Capitain (O)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France.

Véronique Guerin-Meyer (V)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Angers, France.

Judith Raimbourg (J)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Hélène Senellart (H)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Sandrine Hiret (S)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Jean-Luc Raoul (JL)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Emilie Thibaudeau (E)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH